secwatch.observer — SEC 8-K summary
======================================

Issuer:     ACADIA PHARMACEUTICALS INC (ACAD)
CIK:        0001070494
Form:       8-K
Filed at:   2025-02-26T23:59:59+00:00
Accession:  0000950170-25-027759
Event type: earnings
Sentiment:  positive
Materiality: 0.78
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Acadia Q4 net income $143.7M; FY2024 revenue $957.8M (+32%); guides FY2025 rev $1.03-1.095B
--------------------------------------------------------------------------------

- FY2024 total net product sales $957.8M, up 32% YoY; NUPLAZID $609.4M (+11%), DAYBUE $348.4M (+97%).
- Q4 net income $143.7M ($0.86 EPS) vs $45.8M ($0.28 EPS) in Q4 2023; includes $146.5M PRV sale gain.
- FY2024 net income $226.5M ($1.37 EPS) vs net loss of $61.3M ($0.37 loss per share) in FY2023.
- FY2025 guidance: total revenue $1.03-1.095B; NUPLAZID $650-690M; DAYBUE $380-405M; R&D $310-330M; SG&A $535-565M.
- Cash and investments $756.0M at Dec 31, 2024, up from $438.9M; EMA submission for trofinetide completed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1070494/000095017025027759/0000950170-25-027759-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1070494/000095017025027759/acad-20250226.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-027759

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer